J&J's Remicade Adds Malignancy Warning To Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
New language on lymphoma in the Warnings and Adverse Reactions sections of labeling is substantially similar to that of other TNF-inhibitors – Amgen's Enbrel and Abbott's Humira. J&J is issuing a "Dear Doctor" letter to inform physicians of the changes.